Human loss-of-function variants suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson’s disease
Irina M Armean,
Jamie L. Marshall,
Eric Vallabh Minikel,
Julia K Goodrich,
Nicholas M Quaife,
Qingbo S Wang,
Beryl B. Cummings,
Marco A.S. Baptista,
Kalpana M Merchant,
Genome Aggregation Database Production Team,
Genome Aggregation Database Consortium,
James S Ware,
Aki S. Havulinna,
the 23andMe Research Team,
Christina M. Hultman,
Ruth J.F. Loos,
Michele T. Pato,
Patrick F Sullivan,
Daniel G MacArthur
Posted 27 Feb 2019
bioRxiv DOI: 10.1101/561472 (published DOI: 10.1038/s41591-020-0893-5)
Posted 27 Feb 2019
Human genetic variants predicted to cause loss-of-function of protein-coding genes (pLoF variants) provide natural in vivo models of human gene inactivation, and can be valuable indicators of gene function and the potential toxicity of therapeutic inhibitors targeting these genes,. Gain-of-kinase-function variants in LRRK2 are known to significantly increase the risk of Parkinson’s disease,, suggesting that inhibition of LRRK2 kinase activity is a promising therapeutic strategy. While preclinical studies in model organisms have raised some on-target toxicity concerns–, the biological consequences of LRRK2 inhibition have not been well-characterized in humans. Here we systematically analyse pLoF variants in LRRK2 observed across 141,456 individuals sequenced in the Genome Aggregation Database (gnomAD), 49,960 exome sequenced individuals from the UK Biobank, and over 4 million participants in the 23andMe genotyped dataset. After stringent variant curation, we identify 1,455 individuals with high-confidence pLoF variants in LRRK2 , 82.5% with experimental validation. We show that heterozygous pLoF variants in LRRK2 reduce LRRK2 protein levels but are not strongly associated with reduced life expectancy, or with any specific phenotype or disease state. These data suggest that therapeutics that partially downregulate LRRK2 levels or kinase activity are unlikely to have major on-target safety liabilities. Our results demonstrate the value of large-scale genomic databases and phenotyping of human LoF carriers for target validation in drug discovery. : #ref-1 : #ref-2 : #ref-3 : #ref-4 : #ref-5 : #ref-8 : #ref-9
- Downloaded 1,888 times
- Download rankings, all-time:
- Site-wide: 6,573 out of 118,083
- In genomics: 780 out of 6,431
- Year to date:
- Site-wide: 16,801 out of 118,083
- Since beginning of last month:
- Site-wide: 31,375 out of 118,083
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!